Efficacy and safety of esmirtazapine in adult outpatients with chronic primary insomnia: a randomized, double-blind placebo-controlled study and open-label extension

STUDY OBJECTIVES: Esmirtazapine (1.5–4.5 mg) has demonstrated short-term sleep-promoting effects in nonelderly outpatients with chronic insomnia. This phase 3, randomized, double-blind study (NCT00631657) and its open-label extension (NCT00750919) investigated efficacy and safety of long-term esmirt...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Sleep Med
Egile Nagusiak: Ivgy-May, Neely, Hajak, Goeran, van Osta, Gonnie, Braat, Sabine, Chang, Qing, Roth, Thomas
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Academy of Sleep Medicine 2020
Gaiak:
Scientific Investigations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7970588/
https://ncbi.nlm.nih.gov/pubmed/32351205
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5664/jcsm.8526
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak